HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$122.50
+0.54%Year over year
Reported trailing growth
- Revenue
- +41.2%
- EBITDA
- -9.3%
- EBIT
- +36.3%
- EPS
- -21.4%
- Free cash flow
- +49.1%
- Operating cash flow
- +49.4%
Forward estimates
Based on analyst estimates
- Revenue
- +24.9%
- EBITDA
- +124.8%
- EPS
- +183.6%
Three-year CAGR
- Revenue
- +28.4%
- EBITDA
- +22.0%
- EBIT
- +44.2%
- Net income
- +16.2%
- EPS
- +21.3%
- Free cash flow
- +39.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026